A Multicenter Phase I Clinical Trial to Assess the Safety of Two Consecutive Days of SyB L-0501 in Combination With Rituximab to Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma.

Trial Profile

A Multicenter Phase I Clinical Trial to Assess the Safety of Two Consecutive Days of SyB L-0501 in Combination With Rituximab to Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma.

Completed
Phase of Trial: Phase I

Latest Information Update: 27 May 2010

At a glance

  • Drugs Bendamustine; Rituximab
  • Indications B cell lymphoma
  • Focus Adverse reactions
  • Most Recent Events

    • 27 May 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 04 Mar 2010 Positive efficacy and tolerability results have been reported in a SymBio Pharmaceutical media release.
    • 30 Nov 2008 Status changed from not yet recruiting to recruiting, as reported on ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top